PMID- 34235188
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211206
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 8
DP  - 2021
TI  - Correlation of Long Non-coding RNA LncRNA-FA2H-2 With Inflammatory Markers in the 
      Peripheral Blood of Patients With Coronary Heart Disease.
PG  - 682959
LID - 10.3389/fcvm.2021.682959 [doi]
LID - 682959
AB  - Objective: To characterize the expression of long non-coding RNA LncRNA-FA2H-2 in 
      coronary heart disease (CHD) and its correlation with inflammatory markers. 
      Methods: From December 2018 to December 2020, 316 patients at Henan Provincial 
      People's Hospital who complained of chest tightness or chest pain and had 
      coronary angiography to clarify their coronary artery conditions for definitive 
      diagnoses were selected as the study subjects. Plasma was collected to detect 
      white blood cells (WBCs), total cholesterol (TG), triglyceride cholesterol (TC), 
      low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol 
      (HDL-C), apolipoprotein A1 (ApoA1), and C-reactive protein (CRP) levels. Tumor 
      necrosis factor (TNF-alpha), monocyte chemotactic protein 1 (MCP-1), vascular cell 
      adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), 
      and interleukin-6 (IL-6) levels were also measured using ELISA. The expression 
      levels of lncRNA-FA2H-2 were measured using quantitative real-time PCR. The data 
      obtained were analyzed by independent sample t-tests, rank sum tests, regression 
      analyses, Pearson's or Spearman's correlation analyses, and receiver operating 
      characteristic curves. Results: (1) Compared with the control group, the 
      differences in age, sex, diabetes, smoking, drinking, body mass index (BMI), WBC, 
      TC, and LDL-C in CHD were not statistically significant, while the differences in 
      hypertension, TG, HDL-C, ApoA1, and CRP were statistically significant. (2) In 
      the grouping of coronary lesion branches, patients with age, sex, hypertension, 
      diabetes, smoking, drinking, BMI, WBC, TC, LDL-C, HDL-C, and ApoA1 differences 
      were not statistically significant, but TG and CRP differences were statistically 
      significant. (3) The relative expressions of TNF-alpha, MCP-1, VCAM-1, ICAM-1, and 
      IL-6 were significantly upregulated in the CHD group (P < 0.001). (4) The results 
      showed that the relative levels of TNF-alpha, MCP-1, VCAM-1, ICAM-1, and IL-6 between 
      the two comparative analyses (high risk, moderate risk, and low risk groups) were 
      statistically significant. In addition, positive correlations were found between 
      the Gensini score and TNF-alpha, MCP-1, VCAM-1, ICAM-1, and IL-6 in CHD patients. (5) 
      LncRNA-FA2H-2 relative expression in the CHD group was significantly 
      downregulated (P < 0.001). (6) The differences in the expression levels of 
      LncRNA-FA2H-2 were statistically significant between the two comparative analyses 
      (P < 0.01), except between the 2-branch lesion and 3-branch lesion groups. (7) 
      LncRNA-FA2H-2 was not associated with age, sex, hypertension, diabetes, smoking, 
      drinking, BMI, WBC, TG, TC, LDL-C, HDL-C, and ApoA1 (P > 0.05). (8) A correlation 
      was found between LncRNA-FA2H-2 and MCP-1, and VCAM-1, ICAM-1, IL-6, and Gensini. 
      (9) The results indicated that the relative levels of LncRNA-FA2H-2 between the 
      two comparative analyses (high risk, moderate risk, and low risk groups) were 
      statistically significant. A negative correlation was found between the Gensini 
      score and LncRNA-FA2H-2. (10) ROC curve analyses of TNF-alpha, MCP-1, VCAM-1, ICAM-1, 
      and IL-6 in CHD showed the area under the curve (AUC) = 0.832 (0.77, 0.893) with 
      a cut-off value of 290.5, a sensitivity of 73%, and a specificity of 64%; AUC = 
      0.731 (0.653, 0.809) with a cut-off value of 396 and with a sensitivity of 59% 
      and specificity of 79%; AUC = 0.822 (0.757, 0.887) with a cut-off value of 264 
      and with a sensitivity of 72% and specificity of 83%; AUC = 0.794 (0.715, 0.874) 
      with a cut-off value of 201.5 and with a sensitivity of 75% and specificity of 
      65%; AUC = 0.760 (0.685, 0.834) with a cut-off value of 328 and with a 
      sensitivity of 55% and specificity of 90%. (11) ROC curve analysis of 
      LncRNA-FA2H-2 in CHD patients showed AUC = 0.834 (0.688, 0.85) with a cut-off 
      value of 3.155 and with a sensitivity of 85% and specificity of 82%. (12) 
      Logistic analyses showed that TNF-alpha, MCP-1, VCAM-1, IL-6, and LncRNA-FA2H-2 were 
      independent risk factors for CHD. Conclusions: The expression of LncRNA-FA2H-2 
      was reduced and inversely correlated with inflammation-related factors in CHD 
      patients. LncRNA-FA2H-2 may have potential as an inflammatory marker for risk 
      assessment of CHD development.
CI  - Copyright (c) 2021 Guo, Sha, Hu and Li.
FAU - Guo, Fengxia
AU  - Guo F
AD  - Department of Clinical Laboratory, Henan Provincial People' Hospital, People' 
      Hospital of Zhengzhou University, Zhengzhou, China.
FAU - Sha, Yanhua
AU  - Sha Y
AD  - Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou 
      University of Chinese Medicine, Guangzhou, China.
FAU - Hu, Bing
AU  - Hu B
AD  - Department of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Li, Gang
AU  - Li G
AD  - Department of Clinical Laboratory, Henan Provincial People' Hospital, People' 
      Hospital of Zhengzhou University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210621
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
EIN - Front Cardiovasc Med. 2021 Nov 17;8:799848. PMID: 34869704
PMC - PMC8255371
OTO - NOTNLM
OT  - LncRNA-FA2H-2
OT  - coronary heart disease
OT  - inflammatory marker
OT  - long non-coding RNA
OT  - peripheral blood
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/07/09 06:00
MHDA- 2021/07/09 06:01
PMCR- 2021/01/01
CRDT- 2021/07/08 06:45
PHST- 2021/03/19 00:00 [received]
PHST- 2021/05/25 00:00 [accepted]
PHST- 2021/07/08 06:45 [entrez]
PHST- 2021/07/09 06:00 [pubmed]
PHST- 2021/07/09 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2021.682959 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2021 Jun 21;8:682959. doi: 10.3389/fcvm.2021.682959. 
      eCollection 2021.